September 08, 2017
Rafael Pharmaceuticals to Present Late Breaking Data at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
Learn more >>

June 19, 2017
Rafael Pharmaceuticals to Present at 2017 BIO International Convention
Learn more >>

June 05, 2017
Cornerstone Pharmaceuticals, Inc. Announces Corporate Name Change to Rafael Pharmaceuticals, Inc.
Learn more >>

May 22, 2017
Cornerstone Pharmaceuticals to Present at the BioNJ 7th Annual BioPartnering Conference, May 23, 2017
Learn More >>

May 09, 2017
The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
Learn More >>

March 23, 2017
FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound
Learn More >>

February 08, 2017
Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
Learn More >>

January 10, 2017
Cornerstone Pharmaceuticals, Inc. Announces Additions to its Board of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., and Richard Scheller, Ph.D.
Learn More >>

 

December 22, 2016
Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017
Learn More >>

December 05, 2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016
Learn More >>

November 29, 2016
Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer
Learn More >>

November 21, 2016
Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting
Learn More >>

November 10, 2016
IDT Corporation Announces Investment in Cornerstone Pharmaceuticals
Learn More >>

October 06, 2016
Cornerstone Pharmaceuticals Announces Acceptance of Abstract on CPI-613 Pancreatic Cancer
Trial by European Society for Medical Oncology (ESMO) Congress 2016
Learn More >>

September 26, 2016
Cornerstone Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
on Tuesday, September 27, 2016
Learn More >>

February 05, 2016
Cornerstone Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare
Conference on Wednesday, February 10, 2016
Learn More >>

January 22, 2016
Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified
Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic
Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium
Learn More >>

November 23, 2015
Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia to Be Presented at 57th Annual ASH Meeting
Learn More >>

January 21, 2015
Cornerstone Pharmaceuticals Receives Funding through New Jersey’s Technology Business Tax Certificate Transfer Program
Learn More >>

January 12, 2015
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Metastatic Colorectal Cancer
Learn More >>

December 05, 2014
Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613 for the Treatment of B-Cell Non-Hodgkin Lymphoma
Learn More >>

November 13, 2014
Cornerstone Pharmaceuticals’ CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch
Learn More >>

November 06, 2014
Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613 in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting
Learn More >>

October 21, 2014
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma
Learn More >>

October 09, 2014
Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer
Learn more >>

October 07, 2014
Cornerstone Pharmaceuticals’ CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR’s Clinical Cancer Research
Learn More >>

May 14, 2014
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014
Learn More >>

April 18, 2014
Cornerstone Pharmaceuticals’ CPI-613 Data to be Presented at the 2014 Annual American Society of Clinical Oncology (ASCO) Meeting
Learn More >>

March 12, 2014
Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells
Learn More >>

February 28, 2014
Cornerstone Pharmaceuticals Presents Non-Small Cell Lung Cancer Data for CPI-613 at 2014 Special Conference of American Association for Cancer Research
Learn More >>

January 31, 2014
Cornerstone Pharmaceuticals Appoints Dr. Chi Van Dang to Scientific Advisory Board
Learn More >>

December 09, 2013
Cornerstone Pharmaceuticals Presents Updated Phase I Data for CPI-613 at 2013 American Society of Hematology Annual Meeting
Learn More >>

November 13, 2013
Cornerstone Pharmaceuticals to Present on Cancer Metabolism at Target TME 2013 Workshop
Learn More >>

November 11, 2013
Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting
Learn More >>

October 31, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Learn More >>

October 24, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell Lung Cancer
Learn More >>

October 03, 2013
Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome
Learn More >>

September 25, 2013
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome
Learn More >>

August 12, 2013
Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Acute Myelogenous Leukemia
Learn More >>

August 08, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613 for the Treatment of Advanced Bile Duct Cancers
Learn More >>

June 03, 2013
Cornerstone Pharmaceuticals Presents Data at 2013 Annual ASCO Meeting
Learn More >>

May 23, 2013
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 in Patients with Advanced Solid Tumors
Learn More >>

April 30, 2013
Cornerstone Pharmaceuticals Appoints Dr. Sim Fass and Howard Jonas to Board of Directors
Learn More >>

April 22, 2013
Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613 with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
Learn More >>

September 28, 2012
Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism
Learn More >>

September 24, 2012
Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at BioX 2012 Conference
Learn More >>

June 01, 2012
Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613 at 2012 Annual ASCO Meeting
Learn More >>

April 30, 2012
Cornerstone Pharmaceuticals announces publication of case report on treatment of a patient presenting metastatic pancreatic cancer with CPI-613 and gemcitabine combination therapy
Learn More >>

April 02, 2012
Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613 at 2012 Annual AACR Meeting
Learn More >>

December 12, 2011
Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia
Learn More >>

October 26, 2011
Cornerstone Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston
Learn More >>

September 15, 2011
Cornerstone Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology
Learn More >>

September 06, 2011
Cornerstone Pharmaceuticals announces FDA orphan drug designation of CPI-613 for patients with acute myeloid leukemia
Learn More >>

July 25, 2011
Cornerstone Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds
Learn More >>

June 03, 2011
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Learn More >>

March 14, 2011
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
Learn More >>

November 05, 2010
Cornerstone Pharmaceuticals Awarded $490K in Grants Under QTDP Program
Learn More >>

October 11, 2010
Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference
Learn More >>

September 09, 2010
Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences
Learn More >>

August 17, 2010
Cornerstone Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations
Learn More >>

August 05, 2010
Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First-in-Class Anti-Cancer Agent CPI-613
Learn More >>

June 07, 2010
Cornerstone Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development
Learn More >>

April 19, 2010
Cornerstone Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613 for Hematologic Malignancies
Learn More >>

March 22, 2010
Cornerstone Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute
Learn More >>

March 08, 2010
Dr. Robert Shepard Appointed Chief Medical Officer for Cornerstone Pharmaceuticals
Learn More >>

February 08, 2010
Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First- In-Class Anti-Cancer Agent CPI-613
Learn More >>

November 11, 2009
Cornerstone Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects
Learn More >>

November 04, 2009
Leading Oncologist Dr. Robert Shepard Joins Cornerstone Pharmaceuticals as Acting Chief Medical Officer
Learn More >>

October 05, 2009
Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D., to its Scientific Advisory Board
Learn More >>

May 27, 2009
Cornerstone Pharmaceuticals Announces $6M Financing to Further Advance Clinical Trials in Cancer Patients
Learn More >>

May 27, 2009
Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial of CPI-613 for Treatment of Pancreatic Cancer
Learn more >>

September 24, 2008
Cornerstone Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613 for the Treatment of Cancer
Learn More >>

July 24, 2008
Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I / II Clinical Trial of CPI-613 in Cancer Patients by US FDA
Learn More >>